Moderna Vaccine Protects 16 Monkeys From Virus; 30,000 Humans Await

To Know more how you can benefit from the Muslim Times, go to our Homepage or About Us page

monkeys-1296x728-header

The Muslim Times has the best collection of articles for the war against Covid 19, especially the vaccines.

Source: Bloomberg

Moderna Inc.’s vaccine candidate against Covid-19 protected against the virus in a trial that inoculated 16 monkeys, an encouraging step on the path to a defense for humans against the pandemic.

Two injections of the vaccine protected against heavy exposure to the virus at two different levels of dosage, Moderna said in findings published Tuesday in the New England Journal of Medicine. The primates didn’t show any sign of creating enhanced disease, a problem that has occasionally been associated with vaccines.

MODERNA-9

The results, if they hold up in humans, suggest that the vaccine may be able to protect against Covid-19 in both the upper and lower airways. In all the monkeys who got the high doses of the vaccine, no viral replication was detectable in their noses two days after being challenged with the virus, according to the study results. And no viral replication was seen in the lung fluid of 7 of 8 animals in both dose groups after being challenged with the virus. All 16 monkeys showed at least some sign of protection, with limited lung inflammation seen in the lungs of both groups.

While the data is encouraging, a far bigger test is under way for Moderna, involving 30,000 humans. The phase 3 trial to determine the safety and efficacy of the vaccine will begin producing data in November or December. The vaccine uses messenger RNA, a synthetic form of genetic material from the virus designed to nudge the body’s immune system into attack mode. The U.S. government is providing $955 million to help fund the vaccine’s development.

Read further

The best of the Muslim Times’ collection for war against Covid 19:

In this day and age, understanding bacteria and viruses and developing vaccines are national security issues. In my view sizable part of every country’s defense budget should be spent in these pursuits rather than making tanks and other weapons.

For the latest news about drugs and vaccines’ trials please go to: Pharmaceutical-Technology

For the latest health news from BBC, Please click here

Novavax starting human trial of its vaccine in Australia

Kaiser Permanente launches first coronavirus vaccine trial

Corona Fear’s Cure: Chanting from the Bible and the Quran

Can You Chant from the Bible or the Quran to Bliss and Happiness?

Japanese flu drug ‘clearly effective’ in treating coronavirus, says China

Synthetic antibodies might offer a quick coronavirus treatment

The Four Possible Timelines for Life Returning to Normal

The Muslim Times Recommending Universal BCG Vaccination to Fight the Pandemic

Coronavirus: TB Vaccination Trial Started in Melbourne, Australia

The Muslim Times has the best collections in the war against Covid 19 as we are collecting from all the established sources

All of humanity are intimate neighbors: Coronavirus proves it once again

Praise be to God for the Miracle of Our Immune System

USA: 15-minute coronavirus test is here

Does the Ordinary Soap Kill Coronavirus?

Here’s a list of disinfectants you can use against coronavirus

For the number of cases and epidemiology in each country go to: WorldOMeters

DAILY NEW CASES AND DEATHS IN US, CDC SITE

Categories: The Muslim Times, Vaccine

3 replies

  1. Pfizer Inc. is preparing for the novel coronavirus to endure, leading to long-term demand for a seasonal shot to protect against Covid-19.

    The New York pharmaceutical giant and its German partner BioNTech SE are front-runners in the race to develop a Covid-19 vaccine, employing a technology known as messenger RNA that can quickly advance through clinical studies. The companies dosed their first U.S. patient in a late-stage trial Monday, and they could be ready to seek approval from regulators as early as October.

    There has been a growing sense that a one-time vaccine regimen may not be enough to ward off Covid-19 forever. It isn’t clear how long coronavirus antibodies can protect people from the disease, and early trials haven’t yet yielded proof that a shot could prevent infection for an extended period of time.

    Pfizer said it expects that a Covid-19 vaccine could, like the flu shot, be an inoculation that is needed regularly to be effective.

    https://www.bloomberg.com/news/articles/2020-07-28/pfizer-says-covid-could-endure-sees-long-term-need-for-shot?srnd=premium&sref=eGA8az79

  2. (Reuters) – Moderna Inc is in talks with several countries for supply agreements for its experimental coronavirus vaccine, the company said on Wednesday, adding that it had already received about $400 million in deposits for potential supply.

    The company’s vaccine candidate is one of the few to be in the final stages of testing as drugmakers race to develop a safe and effective vaccine against the pandemic that has claimed more than 700,000 lives worldwide.

    Last week, Moderna announced the start of a late-stage trial on 30,000 people to demonstrate that its vaccine was safe and effective, the final hurdle prior to regulatory approval. It has said the vaccine could be ready for widespread use by the end of this year.

    The company, which ended the quarter with $3.1 billion in cash, cash equivalents and investments, said it was on track to complete enrollment in the study in September.

    Moderna said last month it plans to price its coronavirus vaccine in a way that ensures broad access and that it did not intend to conduct late-stage trials of the vaccine outside the United States.

    https://finance.yahoo.com/news/moderna-says-discussing-supply-deals-112510663.html

  3. Moderna is charging between $32 to $37 per dose for its coronavirus vaccine for some customers, under cheaper “pandemic pricing,” the company said Wednesday.

    The Cambridge, Massachusetts-based company is currently in discussion for larger volume agreements that will have a lower price, Moderna CEO Stephane Bancel said on a conference call discussing the company’s second-quarter financial results.

    “We are working with governments around the world and others to ensure a vaccine is accessible regardless of ability to pay,” he said. “We’re currently in a pandemic as defined by WHO. At Moderna, like many experts, we believe the virus is not going away and there will be a need to vaccinate people or give them a boost for many years to come.”

    Moderna defines a small order of its vaccine as “in the millions,” he said. The price Moderna is charging for small orders is higher than the $19.50 per dose agreed to by U.S. drugmaker Pfizer and German biotech BioNTech in a deal with the U.S. government.

    Bancel said the vaccine will be priced “well-below value” during the pandemic period. After the virus is under control and considered endemic, the pricing will follow traditional market pricing in line with other commercial vaccines, he said.

    “We’ll work with the market,” Bancel said.

    https://www.cnbc.com/2020/08/05/moderna-is-pricing-coronavirus-vaccine-at-32-to-37-per-dose-for-some-customers.html

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out /  Change )

Google photo

You are commenting using your Google account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s

This site uses Akismet to reduce spam. Learn how your comment data is processed.